Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 1/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.46 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.46 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 7/20 | 0.46 |
| ▸ | NPC1 | O15118 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4818608 | 0.89 | CYP17A1 (0.46) | MAPTMEN1KMT2ANAMPTALDH1A1 | |
| SCHEMBL2347126 | 0.85 | CYP17A1 (0.47) | MAPTNAMPTMAPK14CA12CA1 | |
| SCHEMBL4822293 | 0.85 | CYP17A1 (0.43) | MAPTKMT2AALDH1A1MAPK14CA12 | |
| SCHEMBL2343259 | 0.85 | PDK1 (0.49) | PDK1PDK2PDK3PDK4MAPT | |
| SCHEMBL273218 | 0.85 | PDK1 (0.60) | PDK1PDK2PDK3PDK4MAPT | |
| SCHEMBL31114069 | 0.83 | NPC1 (0.52) | PDK1PDK2PDK3PDK4MAPT | |
| SCHEMBL18165108 | 0.82 | CA12 (0.48) | RAB9ANPC1SMN1; SMN2CA12CA1 | |
| SCHEMBL2350063 | 0.81 | MAPK14 (0.64) | MAPTRAB9ANPC1MEN1KMT2A | |
| SCHEMBL8728009 | 0.79 | CYP17A1 (0.60) | PDK1PDK2PDK3PDK4MAPT | |
| SCHEMBL3926783 | 0.79 | RAB9A (0.73) | RAB9ANPC1KMT2AGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008303-B2 | e.g. 6-Methyl-biphenyl-3,4'-dicarboxylic acid 4'-[(3-bromo-phenyl)-amide]-[(4 morpholin-4-yl-phenyl)-amide]; viricide; with other active viricide such as interferon or ribavirin | ASTRAZENECA AB (SE) | 2011-08-30 | — | — | US | disclosed |
| US-8008303-B2 | e.g. 6-Methyl-biphenyl-3,4'-dicarboxylic acid 4'-[(3-bromo-phenyl)-amide]-[(4 morpholin-4-yl-phenyl)-amide]; viricide; with other active viricide such as interferon or ribavirin | ASTRAZENECA AB (SE) | 2011-08-30 | — | — | US | disclosed |
| EP-1940786-B1 | BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C | ARROW THERAPEUTICS LTD (GB) | 2010-08-18 | — | — | EP | disclosed |
| EP-1940786-B1 | BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C | ARROW THERAPEUTICS LTD (GB) | 2010-08-18 | — | — | EP | disclosed |
| US-20080255105-A1 | Biphenyl Derivatives and Their Use in Treating Hepatitis C | ARROW THERAPEUTICS LIMITED (GB) | 2008-10-16 | — | — | US | disclosed |
| US-20080255105-A1 | Biphenyl Derivatives and Their Use in Treating Hepatitis C | ARROW THERAPEUTICS LIMITED (GB) | 2008-10-16 | — | — | US | disclosed |
| EP-1940786-A1 | BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C | Arrow Therapeutics Limited (GB) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007031791-A1 | BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C | ARROW THERAPEUTICS LIMITED (GB) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255105-A1 | Biphenyl Derivatives and Their Use in Treating Hepatitis C | NR4A1, NR0B1, NR1H4 | PDK1 4123/4885PDK2 4221/4885PDK3 3705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.